Y-MABS THERAPEUTICS INC's ticker is YMAB and the CUSIP is 984241109. A total of 97 filers reported holding Y-MABS THERAPEUTICS INC in Q2 2023. The put-call ratio across all filers is 0.24 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $171,862 | -20.5% | 14,227 | +7.1% | 0.00% | – |
| Q1 2024 | $216,063 | +138.9% | 13,288 | +0.2% | 0.00% | – |
| Q4 2023 | $90,441 | +40.8% | 13,261 | +12.5% | 0.00% | – |
| Q3 2023 | $64,223 | -19.7% | 11,784 | 0.0% | 0.00% | – |
| Q2 2023 | $80,013 | +18.0% | 11,784 | -12.9% | 0.00% | – |
| Q1 2023 | $67,785 | -3.2% | 13,530 | -5.7% | 0.00% | – |
| Q4 2022 | $70,023 | -71.1% | 14,349 | -14.6% | 0.00% | – |
| Q3 2022 | $242,000 | -86.1% | 16,803 | -85.4% | 0.00% | -100.0% |
| Q2 2022 | $1,745,000 | +869.4% | 115,302 | +661.4% | 0.00% | – |
| Q1 2022 | $180,000 | -26.2% | 15,144 | +0.7% | 0.00% | – |
| Q4 2021 | $244,000 | -48.0% | 15,033 | -8.5% | 0.00% | – |
| Q3 2021 | $469,000 | +0.2% | 16,429 | +18.5% | 0.00% | – |
| Q2 2021 | $468,000 | +82.1% | 13,866 | +63.1% | 0.00% | – |
| Q1 2021 | $257,000 | -18.2% | 8,503 | +34.2% | 0.00% | – |
| Q4 2020 | $314,000 | -91.5% | 6,334 | -92.6% | 0.00% | -100.0% |
| Q2 2020 | $3,674,000 | – | 85,061 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Sofinnova Investments, Inc. | 2,194,278 | $84,238,000 | 6.25% |
| Burrage Capital Management LLC | 123,025 | $4,723,000 | 3.73% |
| MPM BioImpact LLC | 337,291 | $12,949,000 | 3.12% |
| First Light Asset Management, LLC | 608,193 | $23,349,000 | 2.39% |
| Cormorant Asset Management, LP | 1,397,700 | $53,658,000 | 2.06% |
| SPHERA FUNDS MANAGEMENT LTD. | 396,521 | $15,222,000 | 1.50% |
| VIRTUS ALTERNATIVE INVESTMENT ADVISERS, INC. | 801 | $33,000 | 0.61% |
| Artal Group S.A. | 285,028 | $10,942,000 | 0.27% |
| DRIEHAUS CAPITAL MANAGEMENT LLC | 298,213 | $11,448,000 | 0.24% |
| Virtus ETF Advisers LLC | 7,309 | $281,000 | 0.15% |